Core Viewpoint - Lepu Medical (300003) expects a significant increase in net profit for the fiscal year 2025, projecting a range of 800 million to 1.2 billion yuan, representing a growth of 223.97% to 385.95% compared to the previous year's net profit of 247 million yuan [1] Financial Performance - The net profit excluding non-recurring gains and losses is also anticipated to be between 800 million to 1.2 billion yuan, which is an increase of 261.29% to 441.93% from the previous year's figure of 221 million yuan [1] - The core business of cardiovascular interventional products shows steady revenue growth, while the pharmaceutical segment has completed inventory clearance in retail channels, achieving double-digit revenue growth [1] Strategic Developments - The company's subsidiary, Minwei Bio, has licensed its proprietary MWN105 injection to Denmark's Sidera, receiving an initial irrevocable investment of 30 million USD as of December 31 [1] - The company has seen positive results from personnel optimization and organizational restructuring, leading to a decrease in both sales and management expenses [1] Challenges - Despite the positive financial outlook, the company experienced a shift from net gains to net losses in foreign exchange due to fluctuations in international currency markets [1] - The company plans to recognize an impairment provision for goodwill [1]

Core Viewpoint - Lepu Medical (300003.SZ) expects a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Financial Performance - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million and 1.2 billion yuan, with a year-on-year increase of 261.29% to 441.93% [1] - The company's core business in cardiovascular interventional revenue has shown steady growth, while the retail channel inventory clearance in the pharmaceutical sector has been largely completed, resulting in double-digit revenue growth [1] Business Stability and Cash Flow - The traditional business foundation remains solid, providing stable profits and cash flow for the company [1] - The strategic emerging sectors, including innovative drugs and dermatology, have contributed to performance growth, with net cash flow from operating activities increasing by approximately 95% [1]

Core Viewpoint - Lepu Medical announced an expected net profit attributable to shareholders of the listed company for 2025, ranging from 800 million to 1.2 billion yuan [2] Financial Forecast - The company projects a net profit for 2025 between 800 million yuan and 1.2 billion yuan [2]

Group 1 - The core business of cardiovascular interventional products has shown steady revenue growth, while the inventory clearance in the retail channel of the pharmaceutical segment is nearly complete, leading to double-digit revenue growth for Lepu Medical [1] - Lepu Medical forecasts a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [3] - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million to 1.2 billion yuan, with a year-on-year increase of 261.29% to 441.93% [3]

Core Viewpoint - Lepu Medical (300003) forecasts a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Financial Performance - The company's core business in cardiovascular interventional revenue is steadily increasing [1] - The retail channel inventory cleanup in the pharmaceutical sector is nearly complete, leading to double-digit revenue growth [1] - The traditional business foundation remains solid, providing stable profits and cash flow [1] Group 2: Strategic Developments - The strategic emerging sectors, including innovative drugs and dermatology, have contributed to performance growth [1] - The net cash flow from operating activities has increased by approximately 95% [1]

Core Viewpoint - Lepu Medical (300003.SZ) forecasts a net profit of 800 million to 1.2 billion yuan for the year 2025, indicating a year-on-year growth of 223.97% to 385.95% [1] Financial Performance - The company expects a net profit attributable to shareholders of 800 million to 1.2 billion yuan, reflecting a significant increase compared to the previous year [1] - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million to 1.2 billion yuan, with a year-on-year growth of 261.29% to 441.93% [1]

Core Viewpoint - Lepu Medical (300003.SZ) forecasts a net profit attributable to shareholders of 800 million to 1.2 billion yuan for the year 2025, indicating a year-on-year growth of 223.97% to 385.95% [1] Financial Performance - The net profit after deducting non-recurring gains and losses is also projected to be between 800 million to 1.2 billion yuan, reflecting a year-on-year increase of 261.29% to 441.93% [1]

Core Viewpoint - The company expects a net profit of 800 million to 1.2 billion yuan for the fiscal year 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Financial Performance - The core business of cardiovascular interventional revenue is steadily increasing [1] - The retail channel inventory clearance in the pharmaceutical sector's formulation business is nearly complete, achieving double-digit revenue growth [1] - The traditional business foundation remains solid, providing stable profits and cash flow for the company [1] Group 2: Strategic Developments - The strategic emerging sectors, including innovative drugs and dermatology, have contributed to performance growth [1] - The net cash flow generated from operating activities has increased by approximately 95% [1]

Core Viewpoint - Lepu Medical (300003.SZ) expects a net profit attributable to shareholders of 800 million to 1.2 billion yuan for 2025, representing a year-on-year growth of 223.97% to 385.95% [1] Group 1: Business Performance - The growth is primarily driven by steady increases in the cardiovascular interventional business and the completion of inventory clearance in the pharmaceutical retail channel, leading to double-digit growth in formulation revenue [1] - Contributions from innovative drugs and emerging sectors such as dermatology are also significant [1] Group 2: Financial Developments - The company received a $30 million upfront payment for the MWN105 project under a licensing agreement [1] Group 3: Cost Management - Personnel optimization and organizational restructuring have led to a decrease in sales and management expenses [1]

证券代码：300003 证券简称：乐普医疗 公告编号：2026-003 乐普（北京）医疗器械股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1、报告期内公司核心业务心血管植介入营业收入稳中有升，药品板块中制 剂业务零售渠道的库存清理基本完成，营业收入实现双位数增长。传统业务基本 盘稳固，为公司提供了稳定的利润和现金流。此外公司布局的战略新兴板块中， 创新药和皮肤科业务贡献了业绩增量，公司经营活动产生的现金流量净额实现增 长约 95%。 2、报告期内公司控股子公司民为生物将具有自主知识产权的 MWN105 注 1 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 | 项目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司 | 盈利：80,000万元～120,000万元 | 盈利：24,693.77万元 | | 股东的净利润 | 比上年同期增长：223.97%～385 ...